VeriChip Corporation Announces Sale of VeriTrace System to Marylandโs Calvert Memorial Hospital
08 7์ 2009 - 9:30PM
Business Wire
VeriChip Corporation (NASDAQ:CHIP) (๏ฟฝVeriChip๏ฟฝ), a provider of
radio frequency identification (RFID) systems for healthcare and
patient-related needs, announced today that it has sold the
VeriTrace๏ฟฝ system, including 1,000 RFID microchips, for disaster
preparedness and emergency management needs to Calvert Memorial
Hospital in Prince Frederick, Maryland.
The VeriTrace system was created in the aftermath of Hurricane
Katrina where it was used by the Federal Disaster Mortuary
Operational Response Team to help identify, track and account for
the remains of victims from the hurricane.
Marc Poulshock, Vice President of VeriChip๏ฟฝs Implantable and
Emergency Management divisions, said, ๏ฟฝThis latest order, by
Calvert Memorial Hospital, demonstrates the importance that both
medical and emergency management personnel place on the VeriTrace
system and disaster preparedness. We will continue our outreach
with federal, state and local groups to stress the benefits of the
VeriTrace system and the need to be prepared for potential natural
catastrophes, large-scale accidents or acts of terrorism.๏ฟฝ
VeriTrace is designed to assist in the management of emergency
situations and disaster recovery using implantable RFID technology.
The VeriTrace system includes a unique implantable RFID microchip,
a VeriTrace Bluetooth(TM) handheld reader, a customized Ricoh 500SE
Digital Camera capable of receiving both RFID scanned data and GPS
data wirelessly, and a Web-enabled database for gathering and
storing information and images captured during emergency response
operations. This database ensures the precise collection, storage
and inventory of all data and images related to remains and the
associated evidentiary items. This also allows the recreation of an
accurate and complete reconstruction of a disaster setting, crime
scene or similar setting where recreation is necessary.
About VeriChip Corporation
VeriChip Corporation, headquartered in Delray Beach, Florida,
has developed the VeriMed๏ฟฝ Health Link System for rapidly and
accurately identifying people who arrive in an emergency room and
are unable to communicate. This system uses the first
human-implantable passive RFID microchip, cleared for medical use
in October 2004 by the United States Food and Drug Administration.
To complement its healthcare division, VeriChip Corporation
established VeriGreen Energy Corporation in March 2009 to focus and
invest in the clean and alternative energy sector.
For more information on VeriChip, please call 1-800-970-2447, or
e-mail info@verichipcorp.com. Additional information can be found
online at www.verichipcorp.com.
Statements about VeriChip๏ฟฝs future expectations, including
future revenues and earnings from the sale of VeriTrace, and all
other statements in this press release other than historical facts
are ๏ฟฝforward-looking statements๏ฟฝ within the meaning of Section 27A
of the Securities Act of 1933, Section 21E of the Securities
Exchange Act of 1934, and as that term is defined in the Private
Litigation Reform Act of 1995. Such forward-looking statements
involve risks and uncertainties and are subject to change at any
time, and VeriChip๏ฟฝs actual results could differ materially from
expected results. Additional information about these and other
factors that could affect the Company๏ฟฝs business is set forth in
the Company๏ฟฝs various filings with the Securities and Exchange
Commission, including those set forth in the Company๏ฟฝs 10-K filed
on February 12, 2009, under the caption ๏ฟฝRisk Factors.๏ฟฝ The Company
undertakes no obligation to update or release any revisions to
these forward-looking statements to reflect events or circumstances
after the date of this statement or to reflect the occurrence of
unanticipated events, except as required by law.
Verichip (MM) (NASDAQ:CHIP)
๊ณผ๊ฑฐ ๋ฐ์ดํฐ ์ฃผ์ ์ฐจํธ
๋ถํฐ 6์(6) 2024 ์ผ๋ก 7์(7) 2024
Verichip (MM) (NASDAQ:CHIP)
๊ณผ๊ฑฐ ๋ฐ์ดํฐ ์ฃผ์ ์ฐจํธ
๋ถํฐ 7์(7) 2023 ์ผ๋ก 7์(7) 2024